Document:

Unassociated Document

Exhibit 10.2

 

AMENDMENT TO SERIES [A/B] COMMON STOCK PURCHASE WARRANT

 

THIS AMENDMENT TO SERIES [A/B] COMMON STOCK PURCHASE WARRANT (this “Amendment”), dated as of [________], 2013, by and between Oxygen Biotherapeutics, Inc., a Delaware corporation (the “Company”) and [_______] (the “Holder”) amends that certain Series [A/B] Common Stock Purchase Warrant issued by the Company to the Holder with respect to [_____] shares of the Company’s Common Stock and with an Initial Exercise Date of February 27, 2013 (the “Warrant”).  Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to such terms in the Warrant.

RECITALS

WHEREAS, Section 5(l) of the Warrant provides that the Warrant may be amended by the written consent of the Company and the Holder.

NOW, THEREFORE, in consideration of the premises, covenants and agreements set forth herein and of other good and valuable consideration, the receipt and legal sufficiency of which they hereby acknowledge, and intending to be legally bound hereby, the parties hereby agree as follows:

1. Section 3(b) of the Warrant is hereby deleted in its entirety and the following new section 3(b) is inserted in lieu thereof:

b)           Subsequent Equity Sales.  From the Issue Date until such date immediately following the 20 consecutive Trading Days wherein (i) the VWAP for each Trading Day during such 20 Trading Day period exceeds $20.00 (subject to adjustment for reverse and forward stock splits and the like), (ii) the daily dollar trading volume of the Common Stock for each Trading Day during such 20 Trading Day period exceeds $100,000 per Trading Day and (iii) there is an effective registration statement (including the Resale Registration Statement) of the Company that permits the Holder to resell all of the Warrant Shares thereunder, unless the Holder shall have otherwise given prior written consent, neither the Company nor any Subsidiary, at any time while this Warrant is outstanding, shall sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, issuance, grant or any option to purchase or other disposition thereof) any Common Stock or Common Stock Equivalents at an effective price per share less than the Exercise Price then in effect.  If the Company enters into a Variable Rate Transaction, despite the prohibition thereon in the Purchase Agreement, the Company shall be deemed to have issued Common Stock or Common Stock Equivalents at the lowest possible conversion or exercise price at which such securities may be converted or exercised.  Notwithstanding the foregoing, the restrictions in this Section 3(b) shall not apply in respect of an Exempt Issuance.

 

  

1

  

2. Except as specifically provided for herein, all terms of the original Warrant shall remain in full force and effect.

3. This Amendment may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which taken together shall constitute but one and the same instrument.

 

IN WITNESS WHEREOF, the Company and the Holder have caused this Amendment to be signed by their respective officers thereunto duly authorized as of the date first written above.

 

 

	 	
COMPANY:

 

	 	
OXYGEN BIOTHERAPEUTICS, INC.

By:______________________________________

Name: Michael B. Jebsen

Title:   Interim Chief Executive Officer and Chief Financial Officer

 

	 	
HOLDER:

 

	 	
[__________________________]

 

By:______________________________________

Name:

Title:

 

2Unassociated Document

Exhibit 10.3

AMENDMENT TO COMMON STOCK PURCHASE WARRANT

 

THIS AMENDMENT TO COMMON STOCK PURCHASE WARRANT (this “Amendment”), dated as of [________], 2013, by and between Oxygen Biotherapeutics, Inc., a Delaware corporation (the “Company”) and [_______] (the “Holder”) amends that certain Common Stock Purchase Warrant issued by the Company to the Holder with respect to [_____] shares of the Company’s Common Stock and with an Initial Exercise Date of July 23, 2013 (the “Warrant”).  Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to such terms in the Warrant.

RECITALS

WHEREAS, Section 5(l) of the Warrant provides that the Warrant may be amended by the written consent of the Company and the Holder.

NOW, THEREFORE, in consideration of the premises, covenants and agreements set forth herein and of other good and valuable consideration, the receipt and legal sufficiency of which they hereby acknowledge, and intending to be legally bound hereby, the parties hereby agree as follows:

1. Section 3(b) of the Warrant is hereby deleted in its entirety and the following new section 3(b) is inserted in lieu thereof:

b)           Subsequent Equity Sales.  From the Issue Date until such date immediately following the date on which, for 25 Trading Days during any 30 consecutive Trading Days period, (i) the VWAP for each of the 25 Trading Days exceeds $6.50 (subject to adjustment for forward and reverse stock splits and the like) and (ii) the daily dollar trading volume for each Trading Day during such 30 consecutive Trading Days period exceeds $350,000 per Trading Day, unless the Substantial Purchaser shall have otherwise given prior written consent, neither the Company nor any Subsidiary, at any time while this Warrant is outstanding, shall sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, issuance, grant or any option to purchase or other disposition thereof) any Common Stock or Common Stock Equivalents at an effective price per share less than the Exercise Price then in effect.  If the Company enters into a Variable Rate Transaction, despite the prohibition thereon in the Purchase Agreement, the Company shall be deemed to have issued Common Stock or Common Stock Equivalents at the lowest possible conversion or exercise price at which such securities may be converted or exercised.  Notwithstanding the foregoing, the restrictions in this Section 3(b) shall not apply in respect of an Exempt Issuance.

 

  

1

  

 

2. Except as specifically provided for herein, all terms of the original Warrant shall remain in full force and effect.

3. This Amendment may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which taken together shall constitute but one and the same instrument.

 

IN WITNESS WHEREOF, the Company and the Holder have caused this Amendment to be signed by their respective officers thereunto duly authorized as of the date first written above.

 

 

	 	
COMPANY:

 

	 	
OXYGEN BIOTHERAPEUTICS, INC.

 

By:_________________________________________

Name: Michael B. Jebsen

Title:   Interim Chief Executive Officer and Chief Financial Officer

 

	 	
HOLDER:

 

	 	
[__________________________]

 

By:__________________________________________

Name:

Title:

 

2ex10-115.htm

CareView Communications, Inc. 8-K

Exhibit 10.115

 

 

THIRD AMENDMENT TO

NOTE AND WARRANT PURCHASE AGREEMENT

 

This THIRD AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT, dated as of August 20, 2013 (this “Amendment”), is made by and among CAREVIEW COMMUNICATIONS, INC., a Nevada corporation (the “Company”), and the investors identified on the signature pages hereto (together with their respective successors and permitted assigns, the “Investors”).

 

WITNESSETH:

 

WHEREAS, the Company and the Investors are parties to that certain Note and Warrant Purchase Agreement, dated as of April 21, 2011 (as amended from time to time, including without limitation pursuant to a Note and Warrant Amendment Agreement dated as of December 30, 2011 and pursuant to a Second Amendment to Note and Warrant Purchase Agreement dated as of January 31, 2012, the “Purchase Agreement”); and

 

WHEREAS, the parties hereto desire to, subject to the terms and conditions contained herein, amend the Purchase Agreement as set forth herein; and

 

WHEREAS, concurrently with this Amendment, the Company, CareView Communications, Inc., a Texas corporation (“CareView Texas”), CareView Operations, L.L.C., a Texas limited liability company (“CV Operations” and, collectively with the Company and CareView Texas, the “Borrowers”), Comerica Bank (“Comerica”) and Bridge Bank, National Association (“Bridge Bank” and, together with Comerica, the “Lenders”) are executing that certain Third Amendment to Loan and Security Agreement (the “Loan Amendment”) in order to amend certain provisions of that certain Loan and Security Agreement dated as of August 31, 2011 (as amended from time to time, including by that certain First Amendment to Loan and Security Agreement dated as of January 15, 2013) between and among the Borrowers and the Lenders (the “Loan Agreement”).

 

NOW, THEREFORE, in consideration of the mutual promises, representations, warranties and covenants contained herein and in the Purchase Agreement, which represent integral components of the transactions contemplated hereby and thereby and shall be fully enforceable by the parties hereto, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Investors mutually agree as follows:

 

1.   Definitions.  Capitalized terms used in this Amendment but not defined in this Amendment shall have the meanings ascribed to them in the Purchase Agreement.

 

2.   Amendments to Purchase Agreement.  Section 5.3 of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

“5.3           Minimum Cash Balance.  The Company shall at all times maintain a combined cash balance with Comerica and Bridge Bank, or any successor Lenders under the Loan Agreement or lenders under the Company’s primary credit facility from time to time (collectively, the “Deposit Banks”), of not less than the Minimum Cash Amount; provided, that in the event the Company’s cash balance falls below the Minimum Cash Amount, the Company shall have thirty (30) days to cure the resulting default and deposit sufficient funds to restore the requisite minimum cash balance (it being understood, for the avoidance of doubt, that so long as any Notes are outstanding, such thirty day period shall run concurrently and not consecutively with any similar cure period afforded under the Notes, and shall not extend any period under the Notes for purposes of determining whether an Event of Default, as defined in the Notes, has occurred). For purposes of this Section 5.3, (a) the “Minimum Cash Amount” shall mean (i) Five Million Dollars ($5,000,000) at all times other than during the Reduced Minimum Cash Period, and (ii) Four Million Dollars ($4,000,000) during the Reduced Minimum Cash Period, provided that the Company gives the Investors prompt notice (and in any event within two Business Days, as such term is defined in the Notes) of the occurrence of the Reduced Minimum Cash Period Start Date, as defined below; and (b) the “Reduced Minimum Cash Period” means the period from the date that the Company’s combined cash balance with the Deposit Banks is less than Five Million Dollars ($5,000,000) (the “Reduced Minimum Cash Period Start Date”) through the earlier of (i) one hundred twenty (120) days after the Reduced Minimum Cash Period Start Date or (ii) the date (x) the Company’s combined cash balance with the Deposit Banks is equal to or greater than Five Million Dollars ($5,000,000) and (y) Investors receive notice from the Company of the Company’s termination of such Reduced Minimum Cash Period; provided, however, that such Reduced Minimum Cash Period shall not apply more than once during the term of this Agreement.”

 

  

  

  

3.   No Further Amendments.  Except as amended by this Amendment, the Purchase Agreement shall remain in full force and effect in accordance with its terms.

 

4.   Conditions.  The effectiveness of this Amendment is subject to (a) the execution and delivery of this Amendment by the Company and the Investors and the acknowledgement thereof by CareView Texas and CV Operations as indicated on the signature pages hereto, and (b) the execution and delivery of the Loan Amendment by the Borrowers and Lenders thereunder.

 

5.   Company’s Representations and Warranties.  The Company represents and warrants to the Investors as follows:

 

a.   the Company is a Nevada corporation, duly organized, validly existing and in good standing under the laws of the jurisdiction of its formation;

 

b.   the Company has the power and authority to execute, deliver and perform its obligations under this Amendment;

 

c.   the execution, delivery and performance by the Company of this Amendment have been duly authorized by all necessary corporate action and does not and will not require any registration with, consent or approval of, notice to or action by, any Person; and

 

  

- 2 -

  

d.   no Event of Default (as defined in the Notes) shall exist as a result of the consummation of the transactions contemplated by this Amendment or the Loan Amendment.

 

6.   Miscellaneous.

 

a.   Ratification and Confirmation.  The Company acknowledges, agrees and confirms that: (x) the Purchase Agreement and each of the other Transaction Documents, as amended and otherwise modified by the amendments and other modifications specifically provided herein, are and shall continue to be in full force and effect and are hereby in all respects ratified and confirmed; and (y) without limiting the generality of the foregoing clause (x), (i) all obligations, liabilities and Indebtedness of the Company under the Transaction Documents, as amended hereby, constitute “Obligations” (as defined in the Security Agreement) secured by and entitled to the benefits of the security set forth in the Security Agreement and the IP Security Agreement, and the liens and security interests granted in favor of the Investors under the terms of the Security Agreement and the IP Security Agreement are perfected, effective, enforceable and valid and such liens and security interests are, in each case, a first priority lien and security interest (except to the extent otherwise expressly permitted by the Transaction Documents) and such liens and security interests are hereby in all respects ratified and confirmed, and (ii) the shares of Common Stock issuable upon conversion of the Supplemental Closing Notes shall constitute “Registrable Securities” under the Registration Rights Agreement.

 

b.   Expenses.  The Company will pay and bear full responsibility for the reasonable legal fees and other out-of-pocket costs and expenses of the Investors attributable to the negotiation and consummation of this Amendment.

 

c.   Survival.  The representations, warranties, covenants and agreements made herein shall survive any investigation made by any party hereto, the execution and delivery of this Amendment and the closing of the transactions contemplated hereby.

 

d.   Governing Law.  All questions concerning the construction, interpretation and validity of this Amendment shall be governed by and construed and enforced in accordance with the domestic laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether in the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware.  In furtherance of the foregoing, the internal law of the State of Delaware will control the interpretation and construction of this Amendment, even if under such jurisdiction’s choice of law or conflict of law analysis, the substantive law of some other jurisdiction would ordinarily or necessarily apply.

 

e.   Construction.  The Company and the Investors acknowledge that the Company and its independent counsel and the Investors and their independent counsel have jointly reviewed and drafted this document, and agree that any rule of construction and interpretation to the effect that drafting ambiguities are to be resolved against the drafting party shall not be employed.

 

f.   Counterparts; Facsimile and Electronic Signatures.  This Amendment may be executed in any number of counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement.  Counterpart signatures to this Amendment delivered by facsimile or other electronic transmission shall be acceptable and binding.

 

g.   Headings.  The section and paragraph headings contained in this Amendment are for reference purposes only and shall not affect in any way the meaning or interpretation of this Amendment.

 

[Signature Pages Follow]

 

  

- 3 -

  

IN WITNESS WHEREOF, each of the undersigned has duly executed this Third Amendment to Note and Warrant Purchase Agreement as of the date first written above.

	  	COMPANY:
	  	  	  
	  	CareView Communications, Inc., a Nevada corporation
	  	  	  
	  	
By:

	
/s/ Samuel A. Greco

	  	
 

	

Name: Samuel A. Greco

	  	
 

	
Title:CEO

	  	  	  
	  	INVESTORS:
	  	HealthCor Partners Fund, L.P.
	  	By: HealthCor Partners Management L.P., as Manager
	  	By: HealthCor Partners Management, G.P., LLC, as General Partner
	  	  	  
	  	
By:

	
/s/ Jeffrey C. Lightcap       

	  	
Name:

	
Jeffrey C. Lightcap

	  	
Title:

	
Senior Managing Director

	  	  	  
	  	
Address:

	
HealthCor Partners

	  	  	
Carnegie Hall Towers

	  	  	
152 West 57th Street

	  	  	
New York, NY 10019

	  	  	  
	  	  	  
	  	HealthCor Hybrid Offshore Master Fund, L.P.
	  	By: HealthCor Hybrid Offshore G.P., LLC, as General Partner
	  	  	  
	  	
By:

	
/s/ Steven J. Musumeci

	  	
Name:

	
Steven J. Musumeci

	  	
Title:

	
Chief Operating Officer

	  	  	  
	  	
Address:

	
HealthCor Partners

	  	  	
Carnegie Hall Towers

	  	  	
152 West 57th Street

	  	  	
New York, NY 10019

 

  

- 4 -

  

 

	
ACKNOWLEDGED AND AGREED:

	  	  
	
CareView Communications, Inc., A Texas corporation

	  
	
By:

	
/s/ Samuel A. Greco

	
Name:

	
Samuel A. Greco

	
Title:

	
CEO

	  
	
CareView Operations, LLC

	  
	
By:

	
/s/ Samuel A. Greco

	
Name:

	
Samuel A. Greco

	
Title:

	
CEO

 

 - 5 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]